PDT Partners LLC Takes Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

PDT Partners LLC purchased a new position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 37,242 shares of the company’s stock, valued at approximately $931,000. PDT Partners LLC owned approximately 0.05% of Kiniksa Pharmaceuticals at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Kiniksa Pharmaceuticals by 0.6% in the first quarter. Vanguard Group Inc. now owns 2,981,894 shares of the company’s stock worth $58,833,000 after buying an additional 16,595 shares during the last quarter. Braidwell LP grew its holdings in Kiniksa Pharmaceuticals by 40.6% during the 3rd quarter. Braidwell LP now owns 2,894,513 shares of the company’s stock valued at $72,334,000 after purchasing an additional 836,210 shares during the last quarter. Rubric Capital Management LP lifted its stake in Kiniksa Pharmaceuticals by 10.2% in the second quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company’s stock worth $45,165,000 after purchasing an additional 223,094 shares during the last quarter. FMR LLC boosted its position in shares of Kiniksa Pharmaceuticals by 36,925.0% during the third quarter. FMR LLC now owns 696,810 shares of the company’s stock valued at $17,413,000 after buying an additional 694,928 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Kiniksa Pharmaceuticals by 31.2% in the second quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock worth $12,398,000 after buying an additional 157,741 shares during the period. 53.95% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, insider John F. Paolini sold 60,692 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total value of $1,585,275.04. Following the transaction, the insider now owns 52,038 shares of the company’s stock, valued at $1,359,232.56. The trade was a 53.84 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Eben Tessari sold 17,000 shares of Kiniksa Pharmaceuticals stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total transaction of $456,790.00. Following the completion of the transaction, the chief operating officer now directly owns 109,975 shares in the company, valued at $2,955,028.25. This represents a 13.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 95,192 shares of company stock worth $2,479,390 over the last 90 days. Company insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Trading Down 1.1 %

Shares of Kiniksa Pharmaceuticals stock opened at $22.08 on Monday. The stock’s fifty day moving average price is $23.95 and its 200-day moving average price is $22.96. The firm has a market cap of $1.59 billion, a P/E ratio of -157.71 and a beta of 0.35. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $15.82 and a 12 month high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its earnings results on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $112.21 million for the quarter, compared to analysts’ expectations of $111.51 million. During the same period last year, the business posted ($0.20) EPS. The company’s revenue for the quarter was up 67.4% on a year-over-year basis. Analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on KNSA shares. Evercore ISI upped their price objective on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. raised their price target on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Finally, Jefferies Financial Group initiated coverage on shares of Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $36.60.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.